List of Excipients in Branded Drug NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

Excipient Strategy and Commercial Opportunities for Norethindrone Acetate, Ethinyl Estradiol, and Ferrous Fumarate

Last updated: August 27, 2026

Norethindrone acetate 1 mg, ethinyl estradiol 20 mcg, and ferrous fumarate 75 mg is a low-dose combined oral contraceptive commonly commercialized as a 24-day active-tablet regimen followed by four ferrous fumarate tablets. The strongest commercial opportunities are generic substitution, chewable-tablet differentiation, improved taste and mouthfeel, packaging convenience, and line extensions that preserve the established active-ingredient profile.

The formulation has three technical constraints: very low-dose hormone uniformity, acceptable oral disintegration for a chewable dosage form, and control of iron-related taste, color, oxidation, and gastrointestinal tolerability. Excipient selection must support bioequivalence without creating unnecessary formulation differences that increase regulatory risk.

What is the approved composition of norethindrone acetate and ethinyl estradiol with ferrous fumarate?

The principal reference product is Minastrin 24 Fe, a chewable oral contraceptive containing 24 active tablets and four nonhormonal ferrous fumarate tablets. Each active tablet contains:

Component	Amount per active tablet	Function
Norethindrone acetate	1 mg	Progestin
Ethinyl estradiol	20 mcg	Estrogen
Excipients	Product-specific	Dilution, binding, compression, taste, stability
Ferrous fumarate tablets	75 mg per tablet	Iron supplementation during the hormone-free interval

The four ferrous fumarate tablets provide 75 mg of ferrous fumarate each, equivalent to approximately 25 mg elemental iron per tablet. The product is designed for a 28-day cycle: 24 hormone-containing tablets followed by four iron-containing tablets. FDA labeling identifies the product as a chewable tablet that may be swallowed with or without water. (U.S. Food and Drug Administration, 2013)

The exact excipient composition is manufacturer-specific. A generic applicant must establish pharmaceutical equivalence and bioequivalence to the reference product while selecting an excipient system that supports manufacturability, stability, taste, and commercial cost.

What excipient functions are most important in this formulation?

The critical excipient functions are low-dose content uniformity, tablet strength, rapid disintegration, taste masking, iron compatibility, and moisture control.

Low-dose hormone dilution

Ethinyl estradiol is present at only 20 mcg per active tablet. The formulation therefore requires an effective dilution and blending strategy. Suitable fillers may include lactose, microcrystalline cellulose, mannitol, starch derivatives, or combinations of these materials.

Mannitol is attractive for chewable tablets because it has a relatively clean mouthfeel and cooling sensation. Lactose can reduce cost and provide favorable compression, but its sweetness and potential incompatibility profile must be assessed. Microcrystalline cellulose improves compactability but can create a more fibrous or chalky mouthfeel at higher concentrations.

For a low-dose hormone product, blend uniformity is more important than maximizing tablet hardness. Segregation risk can arise from differences in particle size, density, electrostatic behavior, and morphology between the active ingredients and excipients.

Binding and compression

The tablet must resist chipping and friability during packaging while remaining easy to chew. Dry granulation, wet granulation, or direct compression may be feasible depending on the physical properties of the hormone powders and selected diluents.

Potential binders include:

• Povidone
• Copovidone
• Pregelatinized starch
• Low-substituted hydroxypropyl cellulose
• Hydroxypropyl cellulose

Direct compression offers a shorter process and lower equipment burden. It may be commercially attractive if the active ingredients have suitable flow and the excipient blend provides adequate content uniformity. Granulation may improve uniformity and flow but adds process complexity, moisture exposure, and scale-up risk.

Disintegration and chewability

A chewable contraceptive tablet must disintegrate rapidly after chewing or swallowing. Crospovidone, croscarmellose sodium, and sodium starch glycolate are common superdisintegrant options. Their levels should be controlled because excessive use can produce a harsh texture, rapid tablet erosion, or poor mouthfeel.

The target is not simply rapid disintegration. The formulation should produce:

• Low chewing force
• Limited grittiness
• No persistent hormonal aftertaste
• Minimal sticking to teeth
• Acceptable tablet integrity during transport

A functional chewable design may use mannitol as the principal filler, a low level of microcrystalline cellulose or starch for structure, and a carefully optimized superdisintegrant concentration.

How should manufacturers manage taste and mouthfeel?

Taste masking is a central commercial issue because the product is intended to be chewed. Ethinyl estradiol and norethindrone acetate can contribute bitter or medicinal notes. Ferrous fumarate is associated with metallic taste, dark coloration, and potential gastrointestinal complaints.

Taste-masking options

The main formulation strategies are:

1. Flavor and sweetener system
   Aspartame, sucralose, saccharin, acesulfame potassium, xylitol, sorbitol, and mannitol may be considered, subject to product-specific tolerability and regulatory acceptance.

2. Polymer coating or microencapsulation
   Coating hormone or iron particles can reduce immediate taste exposure. This approach may improve acceptability but can increase process cost and introduce dissolution and content-uniformity challenges.

3. Ion-exchange or adsorption technologies
   These methods can reduce bitterness but may complicate release behavior and require strong justification in a generic product.

4. Flavor partitioning
   Citrus, berry, mint, or vanilla systems can reduce perception of hormonal bitterness. Iron-associated metallic notes may require a different flavor architecture than the active-tablet phase.

A two-tablet flavor strategy may be appropriate. The 24 active tablets can use a sweet, low-acid flavor system, while the four iron tablets may require stronger masking and a different colorant system. The iron tablets should not be over-flavored in a way that encourages pediatric-like consumption or creates medication-error concerns.

Excipient safety considerations

Potential excipients require screening for:

• Phenylalanine content from aspartame
• Sugar alcohol-related gastrointestinal effects
• Lactose intolerance considerations
• Dye sensitivity
• Nitrite, peroxide, or aldehyde impurities
• Moisture sensitivity
• Residual solvents
• Elemental impurities

The FDA Inactive Ingredient Database can support regulatory precedent analysis, but precedent alone does not establish suitability for every strength or dosage form. (U.S. Food and Drug Administration, n.d.-a)

What formulation patents and intellectual-property barriers affect the product?

The active ingredients are long-established generic oral contraceptive components. Commercial barriers are more likely to arise from product-specific formulation, chewable-tablet design, manufacturing know-how, trademarks, and regulatory execution than from composition-of-matter protection.

Relevant intellectual-property categories include:

IP category	Potential subject matter	Commercial significance
Formulation patents	Taste masking, chewable matrix, excipient ratios	May affect design-around strategy
Method-of-use patents	Contraceptive administration or cycle regimens	Usually less important for routine generic entry
Manufacturing patents	Granulation, coating, blending, compression	Can affect process selection
Packaging patents	Calendar packs, unit-dose blister systems	May affect packaging design
Trademarks	Brand names and trade dress	Require separate design and clearance
Regulatory exclusivity	NDA exclusivity or pediatric exclusivity	Can delay ANDA approval

The FDA Orange Book is the controlling public source for listed patents and exclusivity associated with approved drug products. A current product-specific review should distinguish between patents listed for the reference NDA, patents that have expired, and patents that may remain enforceable but are not listed in the Orange Book. (U.S. Food and Drug Administration, n.d.-b)

Because this product is a small-molecule oral contraceptive, biosimilar risk is not relevant. The competitive threat is conventional generic competition under the Abbreviated New Drug Application pathway.

What is the FDA regulatory pathway for a generic product?

A generic applicant would generally pursue an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The target product should match the reference product in active ingredients, dosage form, route of administration, strength, and relevant performance characteristics.

Key regulatory workstreams include:

• Pharmaceutical equivalence
• In vitro dissolution
• Assay and content uniformity
• Impurity characterization
• Stability under ICH conditions
• Bioequivalence, where required
• Chewable-tablet performance
• Labeling and package configuration
• Excipient justification
• Manufacturing-process validation

The FDA’s guidance for chewable tablets emphasizes product performance, mechanical properties, disintegration, dissolution, and palatability-related considerations. A chewable product that differs materially in texture or administration instructions may create additional review risk even if the active ingredients are identical. (U.S. Food and Drug Administration, 2018)

A formulation that changes the active tablet from chewable to conventional swallowable form may require a different regulatory strategy and may not qualify as therapeutically equivalent to the same reference product.

When does generic entry risk become commercially meaningful?

Generic entry risk becomes meaningful when three conditions converge:

1. The reference product has no remaining blocking exclusivity.
2. The Orange Book patent position does not prevent ANDA approval or launch.
3. Multiple manufacturers can produce the product at acceptable yield and cost.

For a 24/4 chewable regimen, the commercial launch sequence can differ from ordinary oral contraceptives because the product requires two tablet formulations, coordinated packaging, and reliable calendar labeling. A manufacturer with only a hormone-tablet capability may still need a second iron-tablet process or a qualified contract manufacturer.

Generic launch scenarios

Scenario	Expected market effect
One approved generic	Moderate price pressure; brand may retain prescribing and payer preference
Two to three generics	Greater pharmacy substitution and lower net pricing
Four or more generics	Commodity-style pricing and reduced brand leverage
Authorized generic or licensed equivalent	Faster share capture if supply is reliable
Shortage or manufacturing failure	Temporary price recovery and contract opportunities

The iron tablets are inexpensive relative to the hormone tablets, but they increase packaging and quality-control requirements. A manufacturer that simplifies the iron-tablet process without changing the approved product configuration may achieve a cost advantage.

How strong is the patent estate for this drug combination?

The patent estate is likely to be weaker than that of a newly approved branded medicine because the active ingredients and therapeutic use are mature. The more defensible commercial elements are likely to be product architecture and execution:

• Chewable dosage form
• 24 active tablets plus four iron tablets
• Taste-masking system
• Tablet-coating process
• Moisture-protective packaging
• Manufacturing controls for microgram-level hormone uniformity
• Patient-facing calendar packaging

A formulation patent is commercially stronger when it covers a measurable product attribute that competitors cannot easily reproduce without infringement, such as a defined dissolution profile, taste-masking structure, particle coating, or narrow excipient ratio. Broad claims covering conventional fillers, binders, or flavors are more vulnerable to validity and design-around challenges.

For a generic applicant, the preferred strategy is usually to avoid unnecessary dependence on a potentially encumbered excipient combination. A formulation should use widely accepted excipients, maintain robust pharmaceutical equivalence, and preserve design flexibility.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue several opportunities around this product class.

Premium chewable platforms

A co-processed mannitol-cellulose or mannitol-starch platform could offer improved flow, compressibility, low friability, and smoother mouthfeel. The value proposition is strongest when the supplier provides data on:

• Tablet hardness and friability
• Disintegration after chewing
• Mouthfeel
• Compatibility with low-dose hormones
• Stability under elevated humidity
• Scale-up performance

Taste-masking systems

A ready-to-use taste-masking platform for bitter hormones and iron could reduce formulation-development time. Suppliers may differentiate through coated particles, flavor systems, or polymeric barriers that preserve dissolution.

Iron-compatible excipient systems

Ferrous fumarate creates a distinct compatibility problem. A supplier that demonstrates low peroxide content, low moisture uptake, and reduced discoloration can target oral iron products and combination regimens.

Packaging and moisture control

Blister systems with strong moisture barriers, desiccant integration, and calendarized dosing can reduce tablet degradation and medication errors. Packaging suppliers can compete on child resistance, senior usability, cycle-day labeling, and reduced secondary packaging.

How does this product compare with conventional norethindrone and ethinyl estradiol products?

The main distinction is the progestin form and the dosage format.

Product characteristic	Norethindrone acetate/ethinyl estradiol/iron	Conventional norethindrone/ethinyl estradiol products
Progestin	Norethindrone acetate	Often norethindrone
Estrogen dose	Commonly 20 mcg in the 24/4 product	Varies, often 20 to 35 mcg
Dosage form	Chewable in the reference product	Usually swallowable tablet
Iron tablets	Four ferrous fumarate tablets	Product-dependent
Main formulation challenge	Taste, chewability, low-dose uniformity	Compression, dissolution, stability
Main commercial differentiator	Administration convenience and regimen design	Price, availability, dose selection

Substitution should not be assumed solely from similar ingredient names. Norethindrone acetate and norethindrone are related but are not interchangeable active ingredients for regulatory purposes without the applicable FDA determination.

What revenue exposure and licensing opportunities exist?

Public FDA records establish approval, labeling, patents, and exclusivity, but they do not provide a complete product-level revenue picture. Commercial exposure depends on prescription volume, payer coverage, branded versus generic share, and the number of approved competitors.

The most practical licensing opportunities are:

• Authorized generic commercialization
• Regional rights for Latin America, Asia, or selected European markets
• Contract manufacturing of the iron-tablet phase
• Co-development of chewable or orally disintegrating alternatives
• Excipient licensing for taste masking
• Calendar-pack and adherence packaging partnerships

A licensee with established hormonal oral-solid manufacturing can reduce launch cost by using an existing facility, while an excipient supplier can capture value through a formulation platform rather than a single-product supply agreement.

What manufacturing and geographic barriers matter?

The main manufacturing barriers are process control and supply reliability rather than complex active pharmaceutical ingredient synthesis.

Key risks include:

• Accurate handling of 20 mcg ethinyl estradiol
• Segregation during blending
• Hormone cross-contamination in multiproduct facilities
• Ferrous fumarate color variability
• Moisture-driven stability loss
• Chewable-tablet friability
• Different compression behavior between hormone and iron tablets
• Calendar-pack assembly errors

Geographic opportunities are strongest in markets where oral contraceptive access is expanding and chewable dosage forms have commercial acceptance. Regulatory requirements differ by jurisdiction, particularly for iron-tablet inclusion, contraceptive labeling, excipient limits, and bioequivalence protocols. A U.S. ANDA formulation may not transfer directly to the European, Canadian, or emerging-market regulatory pathway.

What are the key development priorities?

A commercially efficient development program should prioritize:

1. A robust low-dose blending process.
2. A mannitol-centered chewable excipient system.
3. Taste masking that addresses both hormonal bitterness and iron notes.
4. A moisture-resistant blister configuration.
5. Early dissolution comparison against the reference product.
6. Separate stability monitoring for active and iron tablets.
7. A formulation design that avoids unnecessary dependence on narrow excipient claims.
8. A cost model covering two tablet formulations and 28-day packaging.

The highest-value product improvements are likely to be better palatability, lower friability, simpler packaging, and dependable supply rather than major pharmacological differentiation.

Key Takeaways

• The commercially relevant product architecture is a 24/4 regimen with 24 hormone-containing chewable tablets and four ferrous fumarate tablets.
• The most important excipient functions are low-dose content uniformity, chewability, taste masking, rapid disintegration, and moisture control.
• Mannitol, microcrystalline cellulose, starch-based binders, superdisintegrants, sweeteners, flavors, and coated-particle technologies are the principal formulation tools.
• Ferrous fumarate creates separate taste, color, oxidation, and gastrointestinal-tolerability challenges.
• Generic competition, not biosimilar competition, is the central market risk.
• Patent exposure is more likely to involve formulation, manufacturing, packaging, and product-specific patents than active-ingredient exclusivity.
• Commercial opportunities include ANDA development, authorized generics, regional licensing, contract manufacturing, premium excipient systems, and adherence-oriented packaging.
• The principal manufacturing barrier is reliable production of a low-dose chewable hormonal tablet alongside a separate iron-tablet phase.

FAQs

Can ferrous fumarate be replaced with another iron salt?

A substitution would change the approved composition and could affect pharmaceutical equivalence, elemental iron delivery, taste, dissolution, and labeling. It should be treated as a separate regulatory and development strategy.

Is a chewable generic required to taste the same as the reference product?

Exact flavor matching is generally not the commercial objective, but the generic must satisfy applicable quality, labeling, performance, and bioequivalence requirements. Poor palatability can reduce market adoption even when regulatory requirements are met.

What is the best filler for this chewable contraceptive tablet?

Mannitol is often attractive because of its mouthfeel and compressibility, but the best filler depends on blend uniformity, tablet strength, dissolution, taste, moisture sensitivity, and cost. No single excipient is universally optimal.

Can the four ferrous fumarate tablets be manufactured by a separate supplier?

A separate qualified supplier or contract manufacturer may produce the iron-tablet phase, subject to quality agreements, supply-chain controls, process validation, and regulatory disclosure requirements.

Does a new flavor create a new patent opportunity?

Flavor alone generally provides limited exclusivity. Stronger protection may arise from a defined taste-masking composition, coated-particle architecture, dissolution profile, or manufacturing process that produces a measurable product characteristic.

References

1. U.S. Food and Drug Administration. (2013). Minastrin 24 Fe prescribing information. FDA.

2. U.S. Food and Drug Administration. (2018). Quality attribute considerations for chewable tablets: Guidance for industry. FDA.

3. U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.